Kidney disease treatment & trial finder
Choose your kidney diagnosis to see recently approved treatments and actively enrolling clinical trials for that condition — with plain-language evidence and links to ClinicalTrials.gov.
For information only — not medical advice. Always talk to your nephrologist.
Kidney treatment is advancing fast
17 FDA-approved therapies since 2018 — 8 in the last two years — plus 3 trials enrolling now.
New U.S. FDA approvals for a kidney indication, by year — across IgA nephropathy, lupus nephritis, C3 glomerulopathy, FSGS, diabetic and polycystic kidney disease, and more. Sources on each treatment card below. Verified July 2026.
Treatment Options for Your Diagnosis
Foundational care
Start hereBlood-pressure control with ACE inhibitors or ARBs, and SGLT2 inhibitors, are standard first-line therapy for most CKD. Your nephrologist typically starts here.
These are newer and recently approved therapies for IgA nephropathy (Berger disease) — not the full standard of care. Ask your care team whether any fit your situation.
Dual endothelin & angiotensin receptor antagonist
Evidence: 42.8% reduction in proteinuria vs 4.4% with irbesartan.
Source: FDA prescribing information; PROTECT, Lancet 2023Verified 2026-07-18
Oral factor B inhibitor (complement pathway)
Evidence: 38.3% reduction in proteinuria vs placebo at 9 months.
Source: FDA prescribing information; APPLAUSE-IgAN, NEJM 2025Verified 2026-07-18
Anti-APRIL monoclonal antibody
Evidence: Significant proteinuria reduction vs placebo; FDA accelerated approval in 2025.
Source: FDA prescribing information (Voyxact); VISIONARY (Phase 3)Verified 2026-07-18
Selective endothelin A receptor antagonist
Evidence: Meaningful proteinuria reduction vs placebo (ALIGN interim); first selective ETA blocker for IgAN.
Source: FDA prescribing information (Vanrafia); ALIGN (Phase 3)Verified 2026-07-18
Targeted-release budesonide (gut-directed)
Evidence: A 9-month course preserved kidney function vs placebo over 2 years.
Source: FDA prescribing information; NefIgArd, Lancet 2023Verified 2026-07-18
Dual BAFF / APRIL inhibitor (TACI-Fc fusion protein)
Approved treatment: Granted FDA accelerated approval on July 7, 2026 to reduce proteinuria in adults with primary IgAN at risk of progression; long-term kidney-function benefit not yet confirmed.
Evidence: 46% reduction in proteinuria from baseline at week 36 (42% vs placebo) in the Phase 3 ORIGIN trial.
Source: FDA prescribing information (Trutakna); ORIGIN 3, NEJM 2026Verified 2026-07-18
Clinical Trials Related to Your Diagnosis
Actively enrolling studies related to IgA nephropathy (Berger disease). Whether a trial is right for you — and whether you qualify — is decided by the study team together with your nephrologist.
No actively enrolling trials we're tracking for IgA nephropathy (Berger disease) right now.
For information only — this is not medical advice, and nothing here is a recommendation to start, stop, or switch treatment. Every treatment decision should go through your nephrologist.
Conditions covered
Jump straight to treatments and enrolling trials for a specific kidney diagnosis.
Manage your whole kidney journey
Lutango helps you track labs, meals, fluids, blood pressure, medications, and more — built specifically for chronic kidney disease.
Get started free